Drug Farm’s DF-003 gets FDA rare pediatric disease designation for ROSAH Syndrome
Drug Farm, a clinical-stage biopharmaceutical company, has announced that its alpha-kinase 1 (ALPK1) inhibitor, DF-003, has been granted Rare Pediatric Disease (RPD) Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ROSAH Syndrome. This designation is a significant milestone in the development of DF-003, which is currently being evaluated in a […]